ArticleDrug design, development and therapy2026
Association of Perioperative Dexmedetomidine Exposure with Flap Failure After Head and Neck Surgery Flap Reconstruction: A Retrospective Study.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study examined the relationship between perioperative dexmedetomidine exposure and postoperative flap outcomes following head and neck reconstruction. Methods: This cohort study used the TriNetX Research Network to identify adults who underwent head and neck flap reconstruction for malignancy between 2014 and 2024. Perioperative dexmedetomidine exposure and outcomes were ascertained using medication records and Current Procedural Terminology (CPT) codes. Following matching, 2,522 patients per group were analyzed. The primary outcome was flap failure within 30 days of surgery. Secondary outcomes included 30-day blood vessel repair procedures, other flap revisions, mortality, acute kidney injury, and sepsis. Analyses at 14 and 90 days were exploratory. Results: For the primary outcome, the dexmedetomidine group demonstrated lower flap failure rates compared with controls at 30 days (2.6% versus 4.1%; odds ratio [OR] 0.62, 95% confidence interval [CI] 0.45-0.85). Among secondary outcomes, a similar association was observed for blood vessel repair procedures (5.4% vs 7.7%; OR 0.69, 95% CI 0.55-0.87). No significant differences were observed in other outcomes. Exploratory temporal analyses revealed directionally consistent associations at 14 days (flap failure OR 0.54, 95% CI 0.37-0.79) and 90 days (flap failure OR 0.66, 95% CI 0.50-0.87). Sensitivity analyses excluding perioperative blood transfusion recipients and restricting the study to tertiary centers demonstrated directional consistency with the primary findings. Multivariable regression identified dexmedetomidine as independently associated with reduced flap failure (hazard ratio 0.60, 95% CI 0.46-0.78). Conclusion: Perioperative dexmedetomidine exposure is associated with reduced flap failure and blood vessel repair, supporting the need for prospective randomized trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.